2022/04/01 更新

写真a

タカノ ユウコ
高野 悠子
TAKANO Yuko
所属
医学部附属病院 化学療法部 病院助教
職名
病院助教
外部リンク

学位 1

  1. 博士(医学) ( 2018年3月   名古屋大学 ) 

 

論文 19

  1. High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides

    Ueno Shinji, Seino Yusuke, Hidaka Shihomi, Maekawa Ryuya, Takano Yuko, Yamamoto Michiyo, Hori Mika, Yokota Kana, Masuda Atsushi, Himeno Tatsuhito, Tsunekawa Shin, Kamiya Hideki, Nakamura Jiro, Kuwata Hitoshi, Fujisawa Haruki, Shibata Megumi, Takayanagi Takeshi, Sugimura Yoshihisa, Yabe Daisuke, Hayashi Yoshitaka, Suzuki Atsushi

    NUTRIENTS   14 巻 ( 5 )   2022年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nutrients  

    (1) Background: Protein stimulates the secretion of glucagon (GCG), which can affect glucose metabolism. This study aimed to analyze the metabolic effect of a high-protein diet (HPD) in the presence or absence of proglucagon-derived peptides, including GCG and GLP-1. (2) Methods: The response to HPD feeding for 7 days was analyzed in mice deficient in proglucagon-derived peptides (GCGKO). (3) Results: In both control and GCGKO mice, food intake and body weight decreased with HPD and intestinal expression of Pepck increased. HPD also decreased plasma FGF21 levels, regardless of the presence of proglucagon-derived peptides. In control mice, HPD increased the hepatic expression of enzymes involved in amino acid metabolism without the elevation of plasma amino acid levels, except branched-chain amino acids. On the other hand, HPD-induced changes in the hepatic gene expression were attenuated in GCGKO mice, resulting in marked hyperaminoacidemia with lower blood glucose levels; the plasma concentration of glutamine exceeded that of glucose in HPD-fed GCGKO mice. (4) Conclusions: Increased plasma amino acid levels are a common feature in animal models with blocked GCG activity, and our results underscore that GCG plays essential roles in the homeostasis of amino acid metabolism in response to altered protein intake.

    DOI: 10.3390/nu14050975

    Web of Science

    Scopus

    PubMed

  2. Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

    Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁: 67 - 70   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-021-00520-z

    Web of Science

    PubMed

  3. Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer

    Inaishi Takahiro, Shibata Masahiro, Ichikawa Takahiro, Kanda Mitsuro, Hayashi Masamichi, Soeda Ikumi, Takeuchi Dai, Takano Yuko, Tsunoda Nobuyuki, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY REPORTS   47 巻 ( 1 )   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncology reports  

    The platelet isoform of phosphofructokinase (PFKP) is one of the key enzymes in the glycolytic pathway. PFKP is highly expressed in several cancers, and it has been reported to be involved in the progression of cancer cells. However, its oncological role in breast cancer (BC) remains unclear. The present study aimed to evaluate the function of PFKP in BC cells and its expression level in patients with BC. Firstly, the mRNA and protein expression of PFKP was evaluated in BC and non‑cancerous mammary cell lines. Polymerase chain reaction (PCR) array analysis was conducted to evaluate the correlation between PFKP and 84 cancer‑related genes. Then, PFKP knockdown was conducted using small interfering RNA, and cell proliferation, invasiveness and migration were analyzed. Furthermore, the association between PFKP mRNA expression and clinicopathological factors was investigated in 167 patients with BC. PFKP was highly expressed in estrogen receptor‑negative and human epidermal growth factor receptor 2‑negative BC cell lines. PCR array analysis demonstrated that the expression level of PFKP was significantly correlated with that of transforming growth factor‑β1 and MYC proto‑oncogene. PFKP knockdown significantly decreased the proliferation and invasiveness of MCF7, SK‑BR‑3, and MDA‑MB‑231 cells. Furthermore, cell migration was inhibited in SK‑BR‑3 and MDA‑MB‑231 cells. In the clinical specimens, patients with T2/T3/T4, lymph node metastasis, or stage II/III/IV exhibited higher expression of PFKP mRNA than patients with less severe disease. In conclusion, the present findings indicated that PFKP is involved in promoting tumor‑progressive oncological roles in BC cells across different subtypes and is considered a possible novel therapeutic target for BC.

    DOI: 10.3892/or.2021.8220

    Web of Science

    Scopus

    PubMed

  4. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁: 46 - 48   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-021-00515-w

    Web of Science

    PubMed

  5. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁: 49 - 49   2022年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-021-00517-8

    Web of Science

    PubMed

  6. Synaptotagmin 13 & nbsp;Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer

    Ichikawa Takahiro, Shibata Masahiro, Inaishi Takahiro, Soeda Ikumi, Kanda Mitsuro, Hayashi Masamichi, Takano Yuko, Takeuchi Dai, Tsunoda Nobuyuki, Kodera Yasuhiro, Kikumori Toyone

    CURRENT ONCOLOGY   28 巻 ( 5 ) 頁: 4080 - 4092   2021年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Current Oncology  

    Background: Accumulating evidence indicates tumor-promoting roles of synaptotagmin 13 (SYT13) in several cancers; however, no studies have investigated its expression in breast cancer (BC). This study aimed to clarify the significance of SYT13 in BC. Methods: SYT13 mRNA expression levels were evaluated in BC cell lines. Polymerase chain reaction (PCR) array analysis was conducted to determine the correlation between expression levels of SYT13 and other tumor-associated genes. Then, the association of SYT13 expression levels in the clinical BC specimens with patients’ clinicopathological factors was evaluated. These findings were subsequently validated using The Cancer Genome Atlas (TCGA) database. Results: Among 13 BC cell lines, estrogen receptor (ER)positive cells showed higher SYT13 mRNA levels than ER-negative cells. PCR array analysis revealed positive correlations between SYT13 and several oncogenes predominantly expressed in ERpositive BC, such as estrogen receptor 1, AKT serine/threonine kinase 1, and cyclin-dependent kinases 4. In 165 patients, ER-positive specimens exhibited higher SYT13 mRNA expression levels than ERnegative specimens. The TCGA database analysis confirmed that patients with ER-positive BC expressed higher SYT13 levels than ER-negative patients. Conclusion: This study suggests that SYT13 is highly expressed in ER-positive BC cells and clinical specimens, and there is a positive association of SYT13 with the ER signaling pathways.

    DOI: 10.3390/curroncol28050346

    Web of Science

    Scopus

    PubMed

  7. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer

    Shibata Masahiro, Inaishi Takahiro, Ichikawa Takahiro, Shimizu Dai, Soeda Ikumi, Takano Yuko, Takeuchi Dai, Tsunoda Nobuyuki, Kikumori Toyone

    SURGERY TODAY   51 巻 ( 10 ) 頁: 1703 - 1712   2021年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Surgery Today  

    Purpose: Papillary thyroid cancer (PTC) is generally associated with a favorable prognosis. However, some patients have fatal disease, with locally infiltrating tumors or progressive distant metastases; yet few studies have investigated the characteristics of the tumor-progressive gene expression profile in advanced PTC. We conducted this study to clarify the gene expression status in advanced PTC and identify candidate molecules for prognostic biomarkers. Methods: We analyzed 740 tumor-progressive gene expression levels from formalin-fixed paraffin-embedded blocks of samples from six patients with low-risk PTC and six patients with high-risk PTC, using the nCounter PanCancer Progression panel. Then, we investigated the association between the expression levels of focused genes and pathological factors in PTC patients in The Cancer Genome Atlas (TCGA) database. Results: The expression levels of 14 genes in the high-risk PTC specimens were more than two-fold those in the low-risk PTC specimens. In the TCGA database, expression levels of four genes (CCL11, COL6A3, INHBA, and SRPX2) were significantly higher in patients with advanced PTC. Among the patients with advanced PTC, those with high SRPX2 expression levels had poor disease-free survival. Univariate and multivariate analyses revealed that high SRPX2 expression was an independent prognostic factor. Conclusion: Based on the findings of this study, CCL11, COL6A3, INHBA, and SRPX2 are potential biomarkers that indicate advanced PTC. SRPX2, in particular, is considered a prognostic biomarker.

    DOI: 10.1007/s00595-021-02262-0

    Web of Science

    Scopus

    PubMed

  8. 高リスク乳頭癌の遺伝子発現プロファイリング解明を目指した研究

    柴田 雅央, 稲石 貴弘, 一川 貴洋, 添田 郁美, 高野 悠子, 武内 大, 角田 伸行, 菊森 豊根

    日本内分泌学会雑誌   97 巻 ( S.Update ) 頁: 31 - 33   2021年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:一般社団法人 日本内分泌学会  

    DOI: 10.1507/endocrine.97.s.update_31

    CiNii Research

  9. A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

    Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

    ANNALS OF ONCOLOGY   32 巻   頁: S354 - S354   2021年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.annonc.2021.05.764

    Web of Science

  10. Chemotherapy for biliary tract cancer: real-world experience in a single institute

    Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   82 巻 ( 4 ) 頁: 725 - 733   2020年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nagoya Journal of Medical Science  

    The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed the clinical courses of patients who underwent chemotherapy with GC from January 2015 to November 2019. Forty-eight patients underwent the GC regimen. One patient (2.1%) achieved a complete response, seven patients (14.6%) achieved a partial response, 26 patients (54.2) achieved stable disease, 11 patients (22.9%) achieved progressive disease, and 3 patients (6.3%) were not evaluable. The overall response rate was 16.7%. The median overall survival was 14.2 months (95% CI: 13.8–14.6), and the median progression-free survival was 7.7 months (95% CI: 4.2–11.2). Thirty-nine patients (81.3%) experienced grade 3 or higher severe adverse events as follows: 54.2% experienced neutropenia, 20.8% experienced anemia, 12.5% experienced thrombocytopenia and 20.8% experienced biliary tract infection. As a second-line chemotherapy, S-1 was used in seventeen patients, and stable disease was achieved in three patients (17.6%). The GC regimen for biliary tract cancer is effective and safe for unresectable or recurrent biliary tract cancer in routine clinical practice.

    DOI: 10.18999/nagjms.82.4.725

    Web of Science

    Scopus

    PubMed

  11. MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer

    Watanabe Manabu, Shibata Masahiro, Inaishi Takahiro, Ichikawa Takahiro, Soeda Ikumi, Miyajima Noriyuki, Takano Yuko, Takeuchi Dai, Tsunoda Nobuyuki, Kanda Mitsuro, Kikumori Toyone, Kodera Yasuhiro, Nagino Masato

    ONCOLOGY LETTERS   20 巻 ( 5 ) 頁: 198   2020年11月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncology Letters  

    Breast cancer (BC) is the most common malignant tumor in females. Development of novel biomarkers or therapeutic targets may contribute toward the improvement of a patient's prognosis. Marginal zone B and B1 cell-specific protein (MZB1) is an unfolded protein response-related chaperone and mainly exists in the endoplasmic reticulum of B lymphocytes, although little is known regarding its role in BC cells. The present study aimed to investigate the significance of MZB1 expression in BC. To begin with, MZB1 mRNA expression levels in 13 BC cell lines and two non-cancerous mammary cell lines were evaluated. Next, mRNA and protein expression of MZB1 in BC patient tumor specimens was evaluated to assess the association between expression and clinicopathological factors or prognosis. MZB1 mRNA expression levels were detectable in four estrogen receptor (ER)-positive BC cell lines. When ratios of MZB1 mRNA expression levels between BC and non-cancerous specimens were evaluated, patients with stage III disease exhibited a higher ratio than patients with stage 0/I/II disease (P=0.009). Using immunohistochemistry, patients with ER-positive BC more frequently expressed MZB1, compared with patients with ER-negative BC (P=0.003). In patients with ER-positive BC, patients with MZB1-positive BC experienced shorter disease-free survival (DFS) times than patients with negative BC (P=0.026). Multivariate analysis of DFS demonstrated that MZB1 positivity was an independent prognostic factor (P=0.022). The results of the present study suggested that MZB1 expression may be associated with a more advanced stage of BC. Furthermore, in patients with ER-positive BC, MZB1 may be a potential prognostic marker.

    DOI: 10.3892/ol.2020.12059

    Web of Science

    Scopus

    PubMed

  12. RASEF expression correlates with hormone receptor status in breast cancer

    Shibata Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Haruyoshi, Umeda Shinichi, Miwa Takashi, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY LETTERS   16 巻 ( 6 ) 頁: 7223 - 7230   2018年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncology Letters  

    Breast cancer (BC) is the most frequently diagnosed malignant tumor in women worldwide, and the development of new molecules associated with BC is essential for the management of this disease. RAS and EF-hand domain-containing (RASEF) encodes the GTPase enzyme that belongs to the Rab family. Although the effects of this gene have been reported in several malignant tumor types, the role of RASEF in BC has not been completely elucidated. The aim of the present study was to investigate the importance of RASEF expression in BC. RASEF mRNA expression levels were evaluated in BC and non-cancerous mammary cell lines. The association between RASEF mRNA expression levels and clinicopathological factors in 167 patients with BC were then determined. Among the 13 examined BC cell lines, ER-negative/HER2-negative cell lines expressed lower RASEF mRNA levels, when compared with the other examined cell lines (P=0.014). Of the 167 patients examined, patients with negative hormone receptor status exhibited significantly lower RASEF mRNA expression levels (P<0.001). In addition low RASEF expression in BC tissues was associated with negative estrogen receptor status (P<0.001), negative progesterone receptor status (P<0.001), and triple-negative status (P<0.001). Additionally, although the differences were not statistically significant, patients with low RASEF expression levels exhibited poorer disease-free survival (P=0.123) and overall survival (P=0.086) than other patients. The results of the present study indicate that RASEF mRNA expression levels are associated with hormone receptor status in BC.

    DOI: 10.3892/ol.2018.9542

    Web of Science

    Scopus

    PubMed

  13. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma

    Nakanishi Kenichi, Kikumori Toyone, Miyajima Noriyuki, Takano Yuko, Noda Sumiyo, Takeuchi Dai, Iwano Shingo, Kodera Yasuhiro

    CLINICAL NUCLEAR MEDICINE   43 巻 ( 7 ) 頁: 482 - 485   2018年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Clinical Nuclear Medicine  

    Background Age is a prognostic factor for recurrent differentiated thyroid carcinoma (DTC) and may be related to radioactive iodine (RAI) nonavidity. Indications for molecular-targeted drugs (MTDs) are currently limited to RAI-refractory DTC. Demonstrating refractoriness to RAI, mainly indicated by RAI nonavidity, may be a barrier to the introduction of MTDs for elderly patients. The present study was conducted to evaluate the impact of age and histological type on the RAI avidity of recurrent lesions of DTC. Methods Two hundred fifty-eight patients (189 patients with classic papillary thyroid carcinoma [cPTC], 8 patients with follicular variant of papillary thyroid carcinoma, and 61 patients with follicular thyroid carcinoma), who underwent their first RAI whole-body scanning for recurrent DTC at our institution between 2004 and 2013, were retrospectively studied. Radioactive iodine uptake was determined by visible uptake by metastatic lesion(s) in a diagnostic RAI-whole-body scan. Results The prevalence of RAI-avid lung metastases in cPTC indicated a significant, inverse correlation with age (<55 years, 36.2%; ≥55 years, 3%; P < 0.001). By contrast, for follicular thyroid carcinoma, the prevalence of RAI avidity was not influenced by age. Similar tendencies were observed for lymph node metastases. Conclusions Radioactive iodine avidity by metastatic lesions of cPTC in elderly patients, especially those older than 55 years, was seldom demonstrated. Adherence to a strategy of restricting MTD administration after confirmation of RAI refractoriness should be revisited for elderly patients. A strategy of omitting RAI treatment should be taken into account when considering age and histological type.

    DOI: 10.1097/RLU.0000000000002078

    Web of Science

    Scopus

    PubMed

  14. Obesity does not affect peri- and postoperative outcomes of transabdominal laparoscopic adrenalectomy

    Inaishi Takahiro, Kikumori Toyone, Takeuchi Dai, Ishihara Hiromasa, Miyajima Noriyuki, Shibata Masahiro, Takano Yuko, Nakanishi Kenichi, Noda Sumiyo, Kodera Yasuhiro

    NAGOYA JOURNAL OF MEDICAL SCIENCE   80 巻 ( 1 ) 頁: 21 - 28   2018年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nagoya Journal of Medical Science  

    Laparoscopic adrenalectomy is the gold standard procedure for most adrenal tumors. Obesity is considered as a risk factor for surgical complications. This study aimed to evaluate whether obesity affects peri- and postoperative outcomes of transabdominal laparoscopic adrenalectomy using body mass index (BMI). This retrospective study included 98 patients who underwent transabdominal laparoscopic adrenalectomy between January 2011 and December 2016. We divided the patients into 2 groups: non-obese group (BMI < 25 kg/m2) and obese group (BMI ≥ 25 kg/m2). We assessed perioperative outcomes and postoperative complications between the groups. A total of 98 patients were analyzed (70 without obesity and 28 with obesity). There were no significant differences between the non-obese and obese groups regarding operative time (111 vs 107 min; p = 0.795), blood loss (3.5 vs 3.5 ml; p = 0.740), rate of placement of additional trocars (14.3% vs 17.9%; p = 0.657), rate of open conversion (2.6% vs 3.6%; p = 0.853), and postoperative length of hospital stay (6 vs 5 days; p = 0.237). Furthermore, obesity was not a significant risk factor for postoperative complications (postoperative bleeding, wound infection, and pneumonia). There are no significant differences in peri- and postoperative outcomes of transabdominal laparoscopic adrenalectomy in patients with obesity compared with those without obesity. Transabdominal laparoscopic adrenalectomy is feasible and safe for patients with obesity.

    DOI: 10.18999/nagjms.80.1.21

    Web of Science

    Scopus

    PubMed

  15. Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report

    Shibata Masahiro, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Aita Yuichi, Takekoshi Kazuhiro, Kodera Yasuhiro, Kikumori Toyone

    SURGICAL CASE REPORTS   3 巻 ( 1 ) 頁: 131   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40792-017-0408-x

    Web of Science

    PubMed

  16. Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells

    Shibata Masahiro, Kanda Mitsuro, Tanaka Haruyoshi, Umeda Shinichi, Miwa Takashi, Shimizu Dai, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY REPORTS   38 巻 ( 3 ) 頁: 1760 - 1766   2017年9月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncology Reports  

    Breast cancer (BC) is the most common malignant tumor among women worldwide. Development of novel molecular targets is important to improve prognosis of BC patients. Derlin 3 (DERL3) gene is a member of derlin family, and its coding protein is critical to the endoplasmic reticulumassociated degradation mechanism. However, its oncological role in breast cancer remains unclear. This study evaluated DERL3 expression and function in BC. We analyzed DERL3 mRNA in 13 BC and two non-cancerous cell lines, and explored effects of DERL3 knockdown on BC proliferation, invasion and migration. We also evaluated correlation of DERL3 mRNA expression levels with clinicopathological factors and prognosis in 167 BC patients. DERL3 mRNA expression was detected in five (38%) BC cell lines. Inhibiting DERL3 expression significantly decreased proliferation and invasion in BC cells. Specimens from patients with lymph node metastasis had higher DERL3 mRNA expression than those without (P=0.030). Patients in the highest quartile for DERL3 mRNA expression (n=42) were more likely to experience shorter overall survival than other patients (P=0.032). These findings indicate that DERL3 promotes malignant phenotype in BC cells. DERL3 may serve as a potential prognostic marker and therapeutic target for BC.

    DOI: 10.3892/or.2017.5800

    Web of Science

    Scopus

    PubMed

  17. Expression of regulatory factor X1 can predict the prognosis of breast cancer

    Shibata Masahiro, Kanda Mitsuro, Shimizu Dai, Tanaka Haruyoshi, Umeda Shinichi, Hayashi Masamichi, Inaishi Takahiro, Miyajima Noriyuki, Adachi Yayoi, Takano Yuko, Nakanishi Kenichi, Takeuchi Dai, Noda Sumiyo, Kodera Yasuhiro, Kikumori Toyone

    ONCOLOGY LETTERS   13 巻 ( 6 ) 頁: 4334 - 4340   2017年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncology Letters  

    Breast cancer (BC) is the most common malignancy among women. Identifying novel biomarkers to predict prognosis accurately is important in managing this disease. The regulatory factor X1 (RFX1) gene is a member of the regulatory factor X gene family. Its protein reportedly downregulates the proto-oncogene c-myc, but its role in BC has been unclear. In this study, expression and methylation status of RFX1 were determined in BC cell lines. We then evaluated RFX1 mRNA expression levels with regard to clinicopathological factors including postoperative prognosis in 167 patients with BC. Expression of RFX1 was heterogeneous among cell lines, and we found no DNA methylation at the RFX1 promoter region. Patients were categorized into groups with high or low RFX1 expression, based on ratio of RFX1 mRNA expression in BC and adjacent non-cancerous tissues. The high RFX1 group was significantly associated with low T factor (P=0.028), earlier disease stage (P=0.015), positive expression of estrogen receptor (P=0.005) and progesterone receptor (P=0.011), negative expression of human epidermal growth factor receptor 2 (P=0.001). The high RFX1 group experienced more favorable disease-free survival (P=0.007) and overall survival (P=0.013). In multivariate analysis, RFX1 expression was an independent prognostic factor for disease-free survival. Our findings indicate that RFX1 may serve as a prognostic marker for BC.

    DOI: 10.3892/ol.2017.6005

    Web of Science

    Scopus

    PubMed

  18. 甲状腺癌気管浸潤に対する気管端々吻合

    菊森 豊根, 稲石 貴弘, 宮嶋 則行, 安立 弥生, 高野 悠子, 中西 賢一, 野田 純代, 武内 大

    日本内分泌・甲状腺外科学会雑誌   34 巻 ( 2 ) 頁: 98-101   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    <p>気管内腔までの浸潤を伴う甲状腺癌は稀ではあるが,血痰,喀血,呼吸困難などの症状を伴って患者を死に至らしめる重篤な病態である。症例の絶対数が少ないので,切除範囲に対する考え方,気管再建法,周術期管理などについて臨床試験を行うことはほぼ不可能で,比較的症例数が多い施設からの報告があるのみである。ここでは当科における甲状腺癌気管浸潤例に対する気管合併切除および再建の経験を踏まえて,特に膜様部温存気管端々吻合を重点的に紹介する。周到な術前評価,確実な手技,適切な周術期管理により端々吻合再建は安全に施行でき,患者のQOL維持に有用であると考えられる。</p>

    DOI: 10.11226/jaesjsts.34.2_98

  19. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides

    Takano Yuko, Kasai Kenji, Takagishi Yoshiko, Kikumori Toyone, Imai Tsuneo, Murata Yoshiharu, Hayashi Yoshitaka

    PLOS ONE   10 巻 ( 7 ) 頁: e0133812   2015年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PLoS ONE  

    Animal models with defective glucagon action show hyperplasia of islet α-cells, however, the regulatory mechanisms underlying the proliferation of islet endocrine cells remain largely to be elucidated. The Gcg<sup>gfp/gfp</sup> mice, which are homozygous for glucagon/green fluorescent protein knock-in allele (GCGKO), lack all proglucagon-derived peptides including glucagon and GLP-1. The present study was aimed to characterize pancreatic neuroendocrine tumors (panNETs), which develop in the GCGKO mice. At 15 months of age, macroscopic GFP-positive tumors were identified in the pancreas of all the GCGKO mice, but not in that of the control heterozygous mice. The tumor manifested several features that were consistent with pancreatic neuroendocrine tumors (panNETs), such as organoid structures with trabecular and cribriform patterns, and the expression of chromogranin A and synaptophysin. Dissemination of GFP-positive cells was observed in the liver and lungs in 100% and 95%, respectively, of 15-month-old GCGKO mice. To elucidate the regulatory mechanism for tumor growth, PanNET grafts were transplanted into subrenal capsules in GCGKO and control mice. Ki-67 positive cells were identified in panNET grafts transplanted to GCGKO mice 1 month after transplantation, but not in those to control mice. These results suggest that humoral factors or conditions specific to GCGKO mice, are involved in the proliferation of panNETs. Taken together, GCGKO mice are novel animal model for studying the development, pathogenesis, and metastasis panNETs.

    DOI: 10.1371/journal.pone.0133812

    Web of Science

    Scopus

    PubMed

▼全件表示

科研費 1

  1. 乳がん術後薬物療法の治療意思決定に関わるプロセス

    研究課題/研究課題番号:19K16829  2019年4月 - 2023年3月

    科学研究費助成事業  若手研究

    高野 悠子

      詳細を見る

    担当区分:研究代表者 

    配分額:1560000円 ( 直接経費:1200000円 、 間接経費:360000円 )

    近年、乳がん治療は多様化し、患者はあらゆる場面で意思決定を余儀なくされている。過去において推し進められてきた延命のみを目標とした治療から、患者のサバイバーシップを意識した治療に変遷している。患者個人の合併症、リスクを加味した治療が行われるようになっている。治療の幅が広がった一方で、医療者と患者でのShared Decision Making が重要視されるようになっている。患者自身が自分の価値観や生活、家族、人生としっかりと向き合って納得して治療を決める必要があると考えられる。乳がん薬物療法を行う上で、患者自身が意思決定をする上でのプロセスを解明する必要がある。
    近年の医学の進歩により、乳がん患者の予後が改善し、がんサバイバーの増加している。生命維持、予後の改善の目的のみに重点を置く治療から、副作用、費用、がんサバイバーたちのその後の生活に重点を当てた治療まで様々な治療の選択肢が存在する。
    本研究は、日々、多様化する乳がんの術後薬物療法の中で、日本人乳がん患者において術後薬物療法を決定するプロセスを解明することを目的としている。このプロセスを解明するために、まず、日本人乳がん患者において、患者と医療者との間でともに方針を決定することという意味である共同意思決定(Shared Decision Making:SDM)がどのくらい実践されているかを評価し、検討することとし、共同意思決定(SDM)に関する既存の質問紙票である"SDM-Q-9"および"SDM-Q-DOC"の日本語訳および、患者の嗜好に関する質問紙票を用いて、乳がん術後の薬物療法の選択について、本邦における日常臨床での共同意思決定(SDM)の実践状況の評価をするために、「乳がんの術後薬物療法におけるShared Decision Makingの実践状況」という観察研究を名古屋大学医学部附属病院の生命倫理委員会に申請した。現在、当院での乳がん術後の患者で適格基準を満たす患者に対して、試験参加のリクルートおよび、参加同意された患者に対して"SDM-Q-9"および患者の嗜好に関する質問紙票を用いたアンケート調査を実施中である。また、該当する患者の担当医に対しても"SDM-Q-DOC"を用いた調査を並行して行っている。
    本研究は主に患者に対するアンケート調査を行うものであるが、新型コロナウィルスの蔓延のため、患者との実際の診療以外での接触を行うのが難しい状況があった。また、乳がんの周術期薬物療法が、以前は術後の治療が中心であったが、トリプルネガティブ乳がん、HER2陽性乳がんといった一部の乳がんでは、術前治療を行って、治療効果を見ていくことが標準的治療の一つとなりつつあるので、該当患者が想定よりも少なくなっているため該当患者数が当初の予定よりも少なくなっている。
    当初の予定期間よりもより長い期間患者のリクルートを行うことで症例数の蓄積をする。外部の人員を雇うことが難しいので、できる限り院内の研究者で患者への説明を行う。郵便を用いてアンケートの返却を依頼する。